Embecta (NASDAQ:EMBC) Posts Earnings Results

Key Points

• Embecta missed Q2 forecasts with EPS $0.27 vs. $0.42 expected and revenue of $221.8M (down 14.4% y/y), and materially cut FY2026 guidance to $1.015B–$1.035B revenue and adjusted EPS $1.55–$1.75, while lowering free cash flow guidance to $95M–$105M.
• The company expects to close the Owen Mumford acquisition this month (adding the Aidaptus auto‑injector and ~$30M to FY26), while reshaping capital allocation with up to $100M buybacks authorized, the quarterly dividend cut to $0.01, and ~$150M of planned 2026 debt repayment.
• Shares tumbled to $4.22 on heavy volume (market cap ~$250M), institutional ownership is ~93.8%, and analysts are mixed with a consensus rating of "Hold."

Embecta (NASDAQ:EMBC - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported $0.27 earnings per share for the quarter, missing analysts' consensus estimates of $0.42 by ($0.15), FiscalAI reports. Embecta had a net margin of 12.92% and a negative return on equity of 26.66%. The company had revenue of $221.80 million for the quarter, compared to analyst estimates of $235.67 million. During the same quarter in the prior year, the business earned $0.70 earnings per share. Embecta's revenue was down 14.4% on a year-over-year basis. Embecta updated its FY 2026 guidance to 1.550-1.75 EPS.

Here are the key takeaways from Embecta's conference call:

• The quarter missed expectations with Q2 revenue of approximately $222 million (down 14.4% y/y) and full‑year fiscal 2026 revenue guidance cut to $1.015B–$1.035B (organic midpoint ~ $995M), with ~70% of the ~$75M guidance reduction driven by pen needles and much of the share loss concentrated at a single large U.S. customer.
• Profitability and cash outlook were materially revised — adjusted operating margin guidance lowered to 22.25%–23.25%, adjusted EPS to $1.55–$1.75 (from $2.80–$3.00), and free cash flow guidance cut to $95M–$105M (from $180M–$200M), with a higher adjusted tax rate and near‑term dilution from the pending acquisition contributing to the change.
• Embecta expects to close the Owen Mumford acquisition this month (upfront ~GBP100M, up to GBP50M earnouts), which adds the Aidaptus auto‑injector platform and should diversify the portfolio beyond insulin devices, contribute ~$30M in FY26 (4 months) and be accretive over time.
• Strategic execution on GLP‑1 and product portfolio progress continues — ~40% of identified GLP‑1 partners are in active negotiations or contracts, several partners launched co‑packed generics in India, and new market‑appropriate pen needles/syringes are advancing through regulatory submissions and selective commercial launches.
• Capital allocation was reshaped — the board authorized up to $100M in share repurchases, cut the quarterly dividend to $0.01 from $0.15, plans ~$150M of debt repayment in 2026, and has initiated a cost‑structure/organizational review to address the guidance shortfall.

Embecta Price Performance

Shares of EMBC stock traded down $5.03 during trading on Tuesday, reaching $4.22. The company's stock had a trading volume of 2,298,421 shares, compared to its average volume of 805,221. The company has a market capitalization of $249.67 million, a price-to-earnings ratio of 1.71 and a beta of 1.09. The stock's 50-day moving average price is $9.26 and its 200 day moving average price is $11.27. Embecta has a 1-year low of $4.33 and a 1-year high of $15.55.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Larson Financial Group LLC grew its holdings in shares of Embecta by 368.6% in the third quarter. Larson Financial Group LLC now owns 2,001 shares of the company's stock valued at $28,000 after purchasing an additional 1,574 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Embecta by 542.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company's stock valued at $71,000 after purchasing an additional 6,224 shares in the last quarter. Wexford Capital LP acquired a new position in Embecta during the 3rd quarter worth approximately $94,000. Humankind Investments LLC acquired a new position in Embecta during the 2nd quarter worth approximately $111,000. Finally, iSAM Funds UK Ltd acquired a new position in Embecta during the 3rd quarter worth approximately $115,000. Institutional investors and hedge funds own 93.83% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. BTIG Research reiterated a "buy" rating and set a $25.00 price target on shares of Embecta in a research report on Friday, February 6th. Wall Street Zen upgraded shares of Embecta from a "buy" rating to a "strong-buy" rating in a research report on Saturday, March 7th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Embecta in a research report on Wednesday, January 21st. Finally, Mizuho dropped their price target on shares of Embecta from $14.00 to $12.00 and set a "neutral" rating for the company in a research report on Monday, April 13th. One analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $18.50.

About Embecta

Embecta Corp NASDAQ: EMBC is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.